Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.7, and includes a new section on HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check14 days agoChange DetectedThe service alert has been updated to reflect a planned maintenance period beginning on July 25th, with most services being unavailable for over 24 hours starting at 9 PM EDT. The revision number has also changed from v2.16.5 to v2.16.6.SummaryDifference2%
- Check21 days agoChange DetectedA service alert has been added regarding planned maintenance on July 26th, indicating that most services will be unavailable for over 12 hours starting at 6 AM EDT.SummaryDifference4%
- Check28 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check49 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.3%
Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.